
CLAIMS


1. A compound selected from the group consisting of (2R)-2-cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the following formula (I):



(I)

;


(R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutaneamide represented by the following formula (II):



(II)

;

(R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-chloropyrimidin-2-yl)-3-ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropyl acetamide represented by the following formula (III):




(III)

;

and (R)-2-cyclopropyl-2-((1R,3S,5S)-3-((2S, 4S)-1-(5-fluoropyrimidin-2-yl)-

2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the following formula (IV):




(IV)

;

or a pharmaceutically acceptable salt thereof.


2. (2R)-2-Cyclopropyl-2-{(1R,3S,5S)-3-[(3S,4R)-1-(5-fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}acetamide represented by the following formula (I):



(I)

or a pharmaceutically acceptable salt thereof.

3. (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-Fluoropyrimidin-2-yl)-3-methoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-methylbutaneamide represented by the following formula (II):




(II)

or a pharmaceutically acceptable salt thereof .

4. (R)-2-((1R,3S,5S)-3-((3S,4R)-1-(5-Chloropyrimidin-2-yl)-3-


ethoxypiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-2-cyclopropyl acetamide represented by the following formula (III):



(III)

or a pharmaceutically acceptable salt thereof.

5. (R)-2-Cyclopropyl-2-((1R,3S,5S)-3-((2S, 4S)-1-(5-fluoropyrimidin-2-yl)-2-methylpiperidin-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)acetamide represented by the following formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof.

6. A pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.

~~7. An orexin type 2 receptor agonist comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.~~

~~8. A therapeutic agent for narcolepsy comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.~~

~~9. A method of treating narcolepsy, comprising administering to a subject a pharmacologically effective dose of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.~~

~~10. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 for use in the treatment of narcolepsy.~~

~~11. Use of the compound or a pharmaceutically acceptable salt thereof~~

~~according to any one of claims 1 to 5 for the manufacture of a pharmaceutical composition for the treatment of narcolepsy.~~

~~12. A therapeutic agent for cataplexy comprising the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.~~

~~13. A method of treating cataplexy, comprising administering to a subject a pharmacologically effective dose of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5.~~

~~14. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 for use in the treatment of cataplexy.~~

~~15. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 for the manufacture of a pharmaceutical composition for the treatment of cataplexy.~~